Content about Dr. Reddy's Laboratories

April 16, 2014

Dr. Reddy's Labs announced the launch of eszopiclone tablets (C-IV) in 1-mg, 2-mg and 3-mg form. The drug is the generic version of Lunesta (eszopiclone) tablets.

HYDERABAD, India — Dr. Reddy's Labs announced the launch of eszopiclone tablets (C-IV) in 1-mg, 2-mg and 3-mg form. The drug is the generic version of Lunesta (eszopiclone) tablets.

The Lunesta tablets brand and generic combined had sales in the United States of approximately $887 million for the most recent twelve months ending in January 2014, according to IMS Health. Dr. Reddy's eszopiclone tablets 1-mg is available in bottle counts of 30; 2-mg and 3-mg tablets are available in bottle counts of 100.

March 28, 2014

Dr. Reddy's Labs announced that it has launched amlodipine besylate and atorvastatin calcium tablets, a generic version of Caduet.

HYDERABAD, India — Dr. Reddy's Labs announced that it has launched amlodipine besylate and atorvastatin calcium tablets, a generic version of Caduet.

The Caduet tablets brand and generic had sales in the United States of approximately $163 million MAT for the most recent 12 months ended January 2014, according to IMS Health.

March 5, 2014

Dr. Reddy's Labs announced the launch of moxifloxacin hydrochloride tablets — the generic version of Avelox tablets — in 400-mg form.

HYDERABAD, India — Dr. Reddy's Labs announced the launch of moxifloxacin hydrochloride tablets, the generic version of Avelox tablets, in 400-mg form. The drug is available in bottle counts of 30.

Avelox tablets had U.S. sales of approximately $195 million for the 12 months ending in December 2013, according to IMS Health.

 

February 26, 2014

Dr. Reddy's Labs announced that it has launched Sumatriptan Injection USP, Autoinjector System 6-mg/0.5-mL, a generic version of Imitrex STATdose Pen (sumatriptan succinate) 6-mg/0.5-mL.

HYDERABAD, India — Dr. Reddy's Labs announced that it has launched Sumatriptan Injection USP, Autoinjector System 6-mg/0.5-mL, a generic version of Imitrex STATdose Pen (sumatriptan succinate) 6-mg/0.5-mL. The drug is available in a carton containing 2 single-dose prefilled syringes.

Sumatriptan is used to treat acute migraine headaches with or without aura and acute cluster headaches in adults who have been diagnosed with migraine or cluster headaches, according to the company.

February 18, 2014

From 2012 to 2017, global spending on medicines will increase from $205 billion to $235 billion, according to IMS Health. By 2017, 36% of the spend will be on generics, a number that is 9% more than the percentage in 2013.

From 2012 to 2017, global spending on medicines will increase from $205 billion to $235 billion, according to IMS Health. By 2017, 36% of the spend will be on generics, a number that is 9% more than the percentage in 2013.

As a result of the patent cliff, generic drug manufacturers have thrived while branded pharmaceutical manufacturers have suffered. Branded pharmaceutical manufacturers are expected to suffer even more in the coming years, as many more important patents will lose exclusivity.

December 17, 2013

Forty blockbuster drugs will use patent exclusivity in the United States between this year and 2020, according to a new study.

BURLINGTON, Mass. — Forty blockbuster drugs will use patent exclusivity in the United States between this year and 2020, according to a new study.

December 11, 2013

The Food and Drug Administration has approved the first generic versions of a drug used to treat depression and other conditions, the agency said.

SILVER SPRING, Md. – The Food and Drug Administration has approved the first generic versions of a drug used to treat depression and other conditions, the agency said Wednesday.

The FDA announced the approval of generic duloxetine delayed-release capsules manufactured by Aurobindo Pharma, Dr. Reddy's Labs, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries and Torrent Pharmaceuticals.

November 8, 2013

The Food and Drug Administration has approved six generic versions of a drug used to treat gastroesophageal reflux disease, or GERD, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved six generic versions of a drug used to treat gastroesophageal reflux disease, or GERD, the agency said Friday.

The FDA announced the approval of the first generic versions of Eisai's Aciphex (rabeprazole sodium) delayed-release tablets for patients aged 12 and older. The generic products are made by Dr. Reddy's Labs, Kremers Urban Pharmaceuticals, Lupin Pharmaceuticals, Mylan Pharmaceuticals, Teva Pharmaceuticals USA and Torrent Pharmaceuticals.

November 1, 2013

Indian drug maker Dr. Reddy's Labs had sales of $536 million in second quarter 2014 and profits of $110 million, the company said.

HYDERABAD, India — Indian drug maker Dr. Reddy's Labs had sales of $536 million in second-quarter 2014 and profits of $110 million, the company said.

Those figures represented sales growth of 17% and a 76% growth in profits over second quarter 2013. Seventy-nine percent of the company's sales came from generic drugs, including 50% from sales in North America; sales of generics grew by 32% over last year.

September 17, 2013

The Food and Drug Administration has approved an injected drug for the bone marrow disorder myelodysplastic syndrome made by Dr. Reddy's Labs, the company said Tuesday.

HYDERABAD, India — The Food and Drug Administration has approved an injected drug for the bone marrow disorder myelodysplastic syndrome made by Dr. Reddy's Labs, the company said Tuesday.

Dr. Reddy's announced the approval of azacitidine injection in the 100-mg-per-vial strength. The drug is a generic version of Celgene's Vidaza, and Dr. Reddy's plans to launch the product in the near future.

Vidaza had sales of about $378.5 million during the 12-month period ended in July, according to IMS Health.

 

August 23, 2013

Indian drug maker Dr. Reddy's Labs has launched a generic treatment for epilepsy, the company said.

HYDERABAD, India — Indian drug maker Dr. Reddy's Labs has launched a generic treatment for epilepsy, the company said.

Dr. Reddy's announced the launch of divalproex sodium extended-release tablets in the 250-mg and 500-mg strengths, used to treat epileptic seizures. The 250-mg tablets are available in bottle count sizes of 100, while the 500-mg tablets are available in sizes of 100 and 500.

August 12, 2013

Dr. Reddy’s has announced the appointment of Dr. Sripada Chandrasekhar as the president and global head of human resources; he will also be a member of Dr. Reddy’s Management Council.

HYDERABAD, India — Dr. Reddy’s has announced the appointment of Dr. Sripada Chandrasekhar as the president and global head of human resources; he will also be a member of Dr. Reddy’s Management Council. With over 30 years of experience, Dr. Chandrasekhar brings a rare blend of experience across India’s leading firms in Public, Private and Multi-National sectors — both in the early economy areas of steel and manufacturing as well as in the more recent domains of Telecom, IT Services and Consulting.

July 29, 2013

Dr. Reddy's Labs has launched a generic drug used to treat Alzheimer's disease, the company said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug used to treat Alzheimer's disease, the company said.

The Indian drug maker announced the launch of donepezil hydrochloride tablets in the 23-mg strength, a generic version of Eisai and Pfizer's Aricept. The drug is being launched in 30- and 90-count bottles.

Aricept in the 23-mg strength had sales of about $92.6 million during the 12-month period that ended in May, according to IMS Health.

 

July 1, 2013

Dr. Reddy's Labs has launched a generic drug for treating epilepsy, the company said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating epilepsy, the company said.

The Indian generic drug maker announced the launch of lamotrigine extended-release tablets in the 25-mg, 50-mg, 100-mg, 200-mg and 300-mg strengths. The drug is being distributed in bottle sizes of 30.

Lamotrigine extended-release tablets are a generic version of GlaxoSmithKline's Lamictal XR, branded and generic versions of which had sales of $300.5 million during the 12-month period that ended in April, according to IMS Health.

 

June 3, 2013

Dr. Reddy's Labs and Fujifilm have terminated a deal to market generic drugs in Japan, Dr. Reddy's said.

HYDERABAD, India — Dr. Reddy's Labs and Fujifilm have terminated a deal to market generic drugs in Japan, Dr. Reddy's said Monday.

The two had signed a memorandum of understanding in June 2011 to establish a joint venture for developing and manufacturing generics in Japan. The ending of the deal was the result of Fujifilm changing its long-term strategy for the drug business, but Dr. Reddy's said they would continue looking into opportunities for partnerships and alliances in other drug businesses.

April 9, 2013

Generic drug maker Dr. Reddy's Labs will move into a new North America headquarters and set up new laboratory space later this year, the company said Tuesday.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs will move into a new North America headquarters and set up new laboratory space later this year, the company said Tuesday.

The India-based company said it had entered into two lease agreements for a new headquarters and research-and-development center in Princeton, N.J. These include a 75,500-sq.-ft. office space at 107 College Rd East and a 31,000-sq.-ft. office and laboratory at 303 College Rd East.

April 4, 2013

Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

HYDERABAD, India — Dr. Reddy's Labs has launched zoledronic acid injection in the 5 mg-per-100-mL strength, the Indian generic drug maker Thursday.

The drug, launched following its approval by the Food and Drug Administration, is a generic version of Novartis' Reclast and is used to treat osteoporosis. Reclast had sales of $355 million during the 12-month period that ended in February, according to IMS Health.

April 2, 2013

Indian generic drug maker Dr. Reddy's Labs has appointed G.V. Prasad as chairman of the company, Dr. Reddy's said.

HYDERABAD, India — Indian generic drug maker Dr. Reddy's Labs has appointed G.V. Prasad as chairman of the company, Dr. Reddy's said Tuesday.

Prasad is currently vice chairman and CEO and will continue as chairman and CEO.

Meanwhile, Satish Reddy has been appointed vice chairman in addition to his current role as managing director and COO.

 

March 29, 2013

Dr. Reddy's has launched a drug for treating acne, the company said Friday.

HYDERABAD, India — Dr. Reddy's has launched a drug for treating acne, the company said Friday.

The Indian generic drug maker announced the launch of Zenatane (isotretinoin) capsules in the 20-mg and 40-mg strengths. The drug is a therapeutically equivalent generic version of Roche's Accutane. The Food and Drug Administration also approved the drug in the 10-mg strength.

Various versions of the drug had sales of about $309 million during the 12-month period that ended in January, according to IMS Health.

 

March 5, 2013

Generic drug maker Dr. Reddy's Labs has launched a drug used to treat certain cancers, the company said Tuesday.

HYDERABAD, India — Generic drug maker Dr. Reddy's Labs has launched a drug used to treat certain cancers, the company said Tuesday.

Dr. Reddy's announced the launch of injectable zoledronic acid in the 4-mg-per-5-mL strength. The launch followed the Food and Drug Administration's approval of the drug.

The drug is a generic version of Novartis' Zometa. The drug is used to treat cancers that have spread to the bones and multiple myeloma.

CORRECTION: An earlier version of this story misstated the strength of the drug. The story has been corrected.

February 28, 2013

The world market for generic drugs will jump more than 15% this year and reach a global total of $127.8 billion, predicted a report from British market research firm Visiongain.

Generics expected to hit double-digit growth

February 8, 2013

The Food and Drug Administration has given tentative approval to a generic drug for treating hypertension, according to agency records.

 SILVER SPRING, Md. - The Food and Drug Administration has given tentative approval to a generic drug for treating hypertension, according to agency records.

The FDA granted tentative approval to Dr. Reddy's Labs' valsartan tablets in the 40 mg, 80 mg, 160 mg and 320 mg strengths.

The drug is a generic version of Novartis' Diovan. Various versions of the drug had sales of $1.6 billion during the 12-month period that ended in June, according to IMS Health.

January 25, 2013

Dr. Reddy's has launched a drug used for treating allergies, the generic drug maker said Friday.

HYDERABAD, India — Dr. Reddy's Labs has launched a drug used for treating allergies, the generic drug maker said Friday.

The Indian drug maker announced the launch of desloratadine orally disintegrating tablets in the 2.5-mg and 5-mg strengths. The drug is a generic version of Merck's Clarinex Reditabs and is available in unit-dose packages of 30.

The branded version of the drug had sales of about $5.3 million during the 12-month period that ended in November 2012, according to IMS Health.

January 4, 2013

Novo Nordisk has appointed Curtis Oltmans as its corporate VP and general counsel for legal and quality affairs, the company said Friday.

PRINCETON, N.J. — Novo Nordisk has appointed Curtis Oltmans as its corporate VP and general counsel for legal and quality affairs, the company said Friday.

In the new role, for which he will also join the company's U.S. executive team, Oltmans will be handle issues like law, quality, intellectual property, grants and philanthropy for the Danish drug maker's North American business.

January 3, 2013

Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

Dr. Reddy's announced the launch of finasteride tablets in the 1-mg strength, a generic version of Merck's Propecia. As the first company to successfully file for approval of a generic version of the drug, Dr. Reddy's is entitled to 180 days of market exclusivity in which to compete directly with the branded version.

Propecia had sales of about $136 million during the 12-month period that ended in October 2012, according to IMS Health.